echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > FDA accelerates approval of the first achondroplasia treatment for the root cause of the disease

    FDA accelerates approval of the first achondroplasia treatment for the root cause of the disease

    • Last Update: 2021-12-02
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On November 19, 2021, BioMarin Pharmaceutical announced that the U.


    Achondroplasia is mainly manifested by the slow growth of the bones at the base of the limbs, spine and skull.


    Its pathogenesis is due to mutations in the gene encoding fibroblast growth factor receptor 3 (FGFR3), resulting in overactive FGFR3 protein


    ▲In the process of normal bone growth, chondrocytes will continue to form new bones on the growth plate


    This approval is based on the positive results of a phase 3 clinical trial and its open-label extension study


    "Chondroplasia is a lifelong genetic disease caused by bone structural disorders caused by impaired


    Reference materials:

    [1] BioMarin Receives FDA Approval for VOXZOGO™ (vosoritide) for Injection, Indicated to Increase Linear Growth in Children with Achondroplasia Aged 5 and Up with Open Growth Plates.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.